1. Scrip
  2. >>Business

Pharma Unit Drives Bayer; Eylea Out-Performs

 
• By Lucie Ellis-Taitt

Bayer AG's pharmaceutical division delivered strong sales in the third quarter, though blood thinner Xarelto (rivaroxaban) missed expectations.

Bayer AG's pharmaceutical division delivered strong sales in the third quarter, though blood thinner Xarelto (rivaroxaban) missed expectations.

In 3Q, group sales for Bayer were 2% below consensus coming in at €11bn. However, pharma sales met expectations reaching...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.